CONTENTS

PREFACE • • x

CHAPTER 1. ____________________________
CHEMISTRY AND BIOLOGICAL IMPORTANCE OF PYRIMIDINE

1.1 Biological Importance of Pyrimidine 3
1.2 Chemistry of Pyrimidine Ring
   1.2.1 Structure of Pyrimidine 9
   1.2.2 Geometry and Electronic structure of Pyrimidine ring 10
   1.2.3 pka of Pyrimidine 11
1.3 Synthesis of Pyrimidines
   1.3.1 One component synthesis 12
   1.3.2 Two component synthesis 12
   1.3.3 Three component synthesis 13
   1.3.4 Synthesis of Pyrimidines from other heterocycles 13
   1.3.5 Two Component “Principal Synthesis” of Pyrimidines 13

CHAPTER 2. __________________________
DESIGN AND SYNTHESIS OF N-CYANOVINYLFORMAMIDINES
AS POTENT ANTIHYPERLIPIDEMIC AGENTS

2.1 ANTIHYPERLIPIDEMIC AGENTS: A BRIEF REVIEW
   2.1.1 Introduction 30
   2.1.2 Formation of plaques 30
   2.1.3 Biochemistry of lipids 31
2.1.4 Lipoprotein transport in blood
2.1.5 Hormonal regulation of lipoprotein metabolism
2.1.6 Classification of hyperlipidemia
2.1.7 Treatment of hyperlipidemia
   i) Diet therapy
   ii) Non absorbable agents
   iii) Absorbable agents
   iv) Recent advances in therapy of atherosclerosis
2.1.8 Limitations of drug therapy
2.1.9 Conclusions

2.2 SYNTHESIS AND BIOLOGICAL SCREENING OF N-
   CYANOVINYLFORMAMIDINES
2.2.1 Introduction
2.2.2 Aim of present work
   i) Molecular modeling
2.2.3 Results and discussion
   i) Synthetic approach
2.2.4 Physical and spectral characteristics
2.2.5 Pharmacological screening for antihyperlipidemic
   activity
   2.2.5.1 General conditions for experimental animals
   2.2.5.2 Antihyperlipidemic activity of N-cyanovinyl-
        formamidines
   2.2.5.3 Subacute toxicity study of compound 164p
   2.2.5.4 Antihyperlipidemic activity of potential metabolites
        of 164p
   2.2.5.5 Results
   2.2.5.6 Antihyperlipidemic activity of S,N-acetals
   2.2.5.7 Discussions
2.2.6 Experimental
CHAPTER 3.


3.1 Introduction 120
3.2 Present work 120
3.3 Profile of compound N-[2-carbethoxy-2-cyano-1-(p-chloroanilino)vinyl]formamidine, 164p 121
3.4 Development of analytical method for compound N-[2-carbethoxy-2-cyano-1-(p-chloroanilino)vinyl]-formamidine, 164p and its validation 123
   3.4.1 Quantitative estimation of compound 164p 123
   3.4.2 Solid phase extraction of compound 164p at different pH 126
   3.4.3 Development of analytical method for the estimation of compound 164p in plasma 127
      3.4.3.1 Plasma spike study by UV method 127
      3.4.3.2 Plasma spike study by HPTLC method 130
      3.4.3.3 Stability of compound 164p in fresh human plasma 134
   3.4.4 Results 135
3.5 Pharmacokinetic study of compound, 164p 136
   3.5.1 Results 137
3.6 Identification of probable metabolite of compound 164p 137
   3.6.1 Synthesis of probable metabolites of 164p 138
   3.6.2 Physical and spectral characteristics of aminal 195p 138
   3.6.3 Results 139
3.7 Profile of the compound ethyl 3-amino-2-cyano-3-(p-chloroanilino)acrylate, 195p 140
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.8</td>
<td>Analytical method development for compound 195p</td>
<td>142</td>
</tr>
<tr>
<td>3.9</td>
<td>Pharmacokinetic study of compound 195p</td>
<td>144</td>
</tr>
<tr>
<td>3.10</td>
<td>Results</td>
<td>145</td>
</tr>
<tr>
<td>3.11</td>
<td>Discussions</td>
<td>145</td>
</tr>
</tbody>
</table>

**CHAPTER 4.**

**SYNTHESIS OF FUNCTIONALISED PYRIMIDINES FROM N-CYANOVINYLFORMAMIDINES**

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Introduction</td>
<td>150</td>
</tr>
<tr>
<td>4.2</td>
<td>Aim of present work</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>4.2.1 Molecular modeling</td>
<td>150</td>
</tr>
<tr>
<td>4.3</td>
<td>Results and discussion</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>4.3.1 Synthetic approach</td>
<td>152</td>
</tr>
<tr>
<td>4.4</td>
<td>Physical and spectral characteristics</td>
<td>157</td>
</tr>
<tr>
<td>4.5</td>
<td>Pharmacological screening</td>
<td>164</td>
</tr>
<tr>
<td></td>
<td>4.5.1 General conditions for experimental animals</td>
<td>164</td>
</tr>
<tr>
<td></td>
<td>4.5.2 Analgesic activity of 4-chloropyrimidines</td>
<td>164</td>
</tr>
<tr>
<td></td>
<td>4.5.3 Antiinflammatory activity of 4-chloropyrimidines</td>
<td>168</td>
</tr>
<tr>
<td></td>
<td>4.5.4 Results</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>4.5.5 Ulcerogenic potential</td>
<td>172</td>
</tr>
<tr>
<td></td>
<td>4.5.5.1 Results</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>4.5.6 Discussions</td>
<td>173</td>
</tr>
<tr>
<td>4.6</td>
<td>Experimental</td>
<td>177</td>
</tr>
</tbody>
</table>
CHAPTER 5.
NOVEL SYNTHESIS OF 4-BROMOPYRIMIDINES AND CONDENSED 4-BROMO-2-CHLORO/DICHLOROMETHYLPYRIMIDINES

5.1 Introduction
  5.1.1 Reaction of nitriles under acidic conditions 204
  5.1.2 The imidoyl halide 206
  5.1.3 Intramolecular cyclisation of functionalised nitriles to azaheterocycles 209
  5.1.4 Synthesis of condensed pyrimidines through the reaction of nitriles with o-aminocarbonyl compound 214
  5.1.5 One-pot Synthesis of condensed pyrimidines 216

5.2 Aim of present work 224

5.3 Results and discussion
  5.3.1 Synthesis of 4-bromopyrimidines by intramolecular cyclisation of N-cyanovinylamidines 225
  5.3.2 Physical and spectral characteristics of 4-bromopyrimidines 227
  5.3.3 Synthesis of condensed 4-bromo-2-chloro/dichloromethylpyrimidines through the reaction of chloro/dichloroacetonitrile with various o-aminonitriles 230
  5.3.4 Physical and spectral characteristics of condensed 4-bromopyrimidines 233

5.4 Experimental 241
CHAPTER 6
SYNTHESIS AND STRUCTURAL ACTIVITY RELATIONSHIP STUDY OF 4-(SUBSTITUTED AMINO)-2,5,7-TRIMETHYLPYRIDO[3',2':4,5]THIENO-(3,2-d)PYRIMIDINES AS POTENT β1-ADRENOCEPTOR ANTAGONIST WITH β2-ADRENOCEPTOR AGONISTIC ACTIVITY

6.1 Introduction 260
6.2 Aim of present work 261
6.3 Results and Discussions 261
   6.3.1 Synthetic approach 261
   6.3.2 Physical and spectral characteristics 263
6.4 Pharmacological screening 268
   6.4.1 General conditions for experimental animals 268
   6.4.2 Results 272
   6.4.3 Discussion 273
6.5 Experimental 275

SUMMARY ... 285

REFERENCES ... 289

PUBLICATIONS ... 311